The licensing agreement will initially cover DiNAQOR's lead candidate DiNA-001, which is being evaluated for MYBPC3 hypertrophic cardiomyopathy, or HCM.BioMarin, which itself is speculated to be an  M&A target,  said it has the option to extend the license to include DiNAQOR's other pipeline programs on similar terms.